---
title: "Shattuck Labs Signs At-The-Market Sales Agreement With Leerink Partners"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/273432926.md"
description: "Shattuck Labs has signed an at-the-market sales agreement with Leerink Partners to sell up to $75 million of common stock. The sales will occur at market prices, and the company can suspend or terminate the program at any time. The agent will earn a commission of up to 3.0% on gross proceeds. Proceeds will be used for advancing clinical trials, developing additional candidates, and general corporate purposes. The agreement is effective from January 22, 2026, and can be terminated at will."
datetime: "2026-01-22T22:33:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273432926.md)
  - [en](https://longbridge.com/en/news/273432926.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273432926.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/273432926.md) | [English](https://longbridge.com/en/news/273432926.md)


# Shattuck Labs Signs At-The-Market Sales Agreement With Leerink Partners

Shattuck Labs entered into a Sales Agreement with Leerink Partners to offer and sell up to $75 million of common stock through an at-the-market program. Sales, if any, may be made at market prices, and the company may suspend or terminate the program at any time. The agent will receive up to a 3.0% commission on gross proceeds. Shattuck plans to use any proceeds to advance clinical trials, develop additional candidates, and for working capital and general purposes.

**Agreement details:**

-   **Agreement type**: At-the-market equity offering sales agreement for up to $75 million
-   **Counterparty**: Leerink Partners
-   **Signed / Effective**: Jan 22 2026 / same
-   **Duration / Termination**: At will
-   **Reason**: Fund clinical trials and general corporate purposes

Original SEC Filing: Shattuck Labs, Inc. \[ STTK \] - 8-K - Jan. 22, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### 相關股票

- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [Shattuck Labs (STTK.US)](https://longbridge.com/zh-HK/quote/STTK.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)

## 相關資訊與研究

- [BUZZ-MiNK Therapeutics rises as it wins funding for child cancer cell therapy](https://longbridge.com/zh-HK/news/278530484.md)
- [10:41 ETBota uruchamia SAION AI - platformę fizycznej sztucznej inteligencji dedykowaną bioprodukcji](https://longbridge.com/zh-HK/news/278742287.md)
- [Altimmune Details Pemvidutide MASH Path: Breakthrough Therapy, FDA Feedback, Phase 3 Next Up](https://longbridge.com/zh-HK/news/278790627.md)
- [Allogene Therapeutics Faces Trial Setback as ALLO-647 Halt Raises Lymphodepletion and Regulatory Timeline Risks](https://longbridge.com/zh-HK/news/279113385.md)
- [BioMarin Pharmaceutical Highlights Growth Plan, VOXZOGO Milestones, and Amicus Deal at Conference](https://longbridge.com/zh-HK/news/279015256.md)